We have collected information about Aln-Rsv01 Delivery for you. Follow the links to find out details on Aln-Rsv01 Delivery.
https://www.alnylam.com/web/Files/Media_Kit/ALNY-RSV-overview-080901.pdf
Those receiving ALN-RSV01 will have drug administered by inhalation via nebulizer which is the expected delivery formulation for commercialization. As a secondary objective, this trial will be the first to evaluate the anti-viral activity of ALN-RSV01 in a naturally acquired RSV lower respiratory tract infection.
https://www.biospace.com/article/releases/pari-pharma-s-eflow-delivers-alnylam-rnai-therapeutic-in-phase-i-study-/
Dec 13, 2007 · To deliver ALN-RSV01 to the site of infection, the siRNA is being administered as an aerosol in a highly efficient pulmonary delivery system, the optimized eFlow(R) electronic nebulizer, with high drug output, optimized droplet size, and low residual drug loss. About eFlow
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2096447/
Dec 03, 2007 · Alnylam Pharmaceuticals recently completed two phase I clinical trials with their siRNA targeting RSV, ALN-RSV01, to evaluate its safety, tolerability, and pharmacokinetics in healthy adult volunteers. A total of 100 human subjects received ALN-RSV01 either as a single dose or as multiple daily doses in the form of a nasal spray.Author: Saghir Akhtar, Ibrahim F. Benter
https://www.sciencedirect.com/science/article/pii/S105324981501387X
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. Author links open overlay panel Jens Gottlieb MD a Martin R. Zamora MD b Tony Hodges MD c A.W. Musk MD d Urte Sommerwerk MD e Daniel Dilling MD, ...Author: Jens Gottlieb, Martin R. Zamora, Tony Hodges, A.W. Musk, Urte Sommerwerk, Daniel Dilling, Selim Arca...
https://meridianlifescience.com/documents/Alnylam%20Poster.pdf
ALN- RSV01 is an siRNA utilizing this RNAi pathway targeting RSV and achieves ≈4 log reductions in virus in vivo with a single 2mg/kg dose delivered topically to the respiratory tract. ALN-RSV01 is the first RNAi based therapy to be tested in humans that targets an infectious disease
https://www.alnylam.com/web/Files/Events/ALNY-RNAiRoundtable-Delivery-090625.pdf
ALN-RSV01 N2 L1 L2 L3 siRNA i.n. (25-100ug) 4 hrs Virus (RSV/A 2) i.n. (106 pfu) 4 days Viral Titer in Lung P gene N gene L gene RSV Symposium, Aug. 2005 18. ALN-RSV01 Phase II GEMINI Study Human POC for RNAi Therapeutics ... •A third delivery strategyA third delivery strategy – …
Searching for Aln-Rsv01 Delivery?
You can just click the links above. The data is collected for you.
